GCP
AARD

GSA Capital Partners’s Aardvark Therapeutics AARD Stock Holding History

GSA Capital Partners’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$102K Sell
27,085
-8,839
-25% -$91.6K 0.01% 1561
2025
Q4 		$472K Buy
+35,924
New +$448K 0.04% 855

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

GSA Capital Partners's AARD Position: Q1 2026 in Review

GSA Capital Partners reduced its Aardvark Therapeutics (AARD) stake by 25% in Q1 2026, selling an estimated $91.6K and leaving 27,085 shares worth $102K. The position accounts for 0.01% of the portfolio, ranked #1561.

GSA Capital Partners first reported a position in AARD in Q4 2025 and has held it in 2 quarters since. The position peaked at $472K in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • GSA Capital Partners held 27,085 shares of Aardvark Therapeutics worth $102K as of Q1 2026.
  • GSA Capital Partners sold 8,839 Aardvark Therapeutics shares in Q1 2026, an estimated $91.6K.
  • Aardvark Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q1 2026, its #1561 holding.
  • GSA Capital Partners first reported a position in Aardvark Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • GSA Capital Partners's Aardvark Therapeutics position peaked at $472K in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.